this is archive.php

MDS UK Patients’ Poems on MDS World Awareness Day

The 25th of October is MDS World Awareness Day

Throughout the day, MDS UK and the international umbrella organisation MDS Alliance will posting on social media moving poems by our dear MDS UK member, Kate D, and other MDS UK members, written on the theme of living with Myelodysplastic Syndrome. 

I long for a cure one day

by Kes Grant

Myelo Dysplastic Syndrome the thief that stole my life
Myelo dysplastic syndrome my nemesis and daily strife.
The gift that keeps on giving from sepsis, fatigue and blood
To platelets, GCSF and transplants
I sometimes wonder how I’m stood
I long for a cure one day

Myelo dysplastic syndrome you have my body but not my spirit
I will strive, and wriggle and struggle,
my mind strong as I go through it
My family suffer as do my friends and that I really hate
Seeing the pain and worry on their faces as they wait to hear my fate
I long for a cure one day



Chemo and transplant offer a possible cure for some
You think all is well then GvHD comes along
Now my quality of life is poor and often rotten
I spend weeks and months feeling awful
Not wanting to hit rock bottom
I long for a cure one day

Strangely I can say it’s not always difficult and bad
People rally round and that makes me glad
I’m glad to be alive to see the grandkids grow
And I remind myself I’m still breathing when I feel low
Keep breathing Kes till they find that cure

My Day Starts

by Kate D.

My Day Starts as
Many Dawns Stretch
over the horizon
and beautify the sky
with shades of
Magenta, Damson and Sky-blue.

Then I remember –
My Disease Sits with me -
every day- not as comfy
as I’d like, but
My Dear Spouse
is there to support me
through appointments and
More Doctors’ Suggestions.

My Doctor States that
positivity is helpful
and that I must be
Mentally Determined to Survive.

I hear of others
Making Daily Strides.
Some wait for Marrow
to be Delivered Soon from
those Marrow Donor
Superheroes who enable us
to say that Many Do Survive.

More Delightful Sunshine
beckons; a world of warmth
in attitude. as virtual friends
support and encourage,
Many Dreams Surface,
hope is given;

May Dreams Succeed in
Assisting acceptance of
Our disease.

So, My Day Starts and
Perhaps My Daily Struggle,
With friendship and support
Means My Day is Sorted.

I’m alive, alive, alive.

By Chris Davis

I opened the door this morning and,
The garden was full of birds,
Birds singing, chirping, washing, flying, laughing,
They were in amongst the flowers,

The flowers of all colours alive with movement,
In the light breeze, as if dancing with the joy of life.
I looked up and the sky was blue, deep, deep blue,
With puffs of cloud floating, suspended, white,
Like giant cotton balls, always moving onwards.


The sun was smiling and so warm, yet,
Tempered by the light caressing movement of the wind,
The same light wind that gives life to the flowers,
The beautiful flowers.

I cried when I saw the birds.
I cried when I saw the sky,
I cried when I felt the sun and,
Was touched by the wind, and,
I cried when I when I saw and felt,
The sheer beauty of the flowers.

Then I looked at it all again,
And I cried out,
“It's good to be alive, to really be alive.”

7.35 to Waterloo

By Chris Davis

Squeaking along,
In a train full of meat,
Going to to London,
God knows who to meet,

No one is talking,
They are all on the phone,
They need that connection,
To prove they're not alone.


By Kate D.

Friendship is my medication.
A hug, a look;
language that is not used
or known by those who
are not in the know;
caught up in the new
jargon that this
disease offers us.

My despicable cancer
has enabled new friendships,
renewed old and erased others.
Around coffee cups we sit,
or we walk and talk about…
all sorts; sometimes
cancer, sometimes not.

I am after all, a normal person
trying to accept what
has had to become
my new normality.

Heart and Soul

by Chris Davis

No, I don't believe we'll part,
Never, ever,
Ever you'll be my lover,
My shoulder when you suffer,
My soul is yours,
And yours is mine,
Even when we have no time,
And we lay together,
In peace forever.



On earth it was the the time to meet,
And find our love,
Is forever deep,
Enough to greet,
The final rest,
The final breath,
The final beat,
Within our breast.

Heavy Luggage

I waited at the station with my little case on wheels,
I worried about lifting it because of the heaviness it feels,
Then the thought of you waiting patiently at another end,
I knew that I could do it and not disappoint a friend.

I waited at the airport with my iphone in my hand,
Not to take a photo because I wasn’t feeling grand,
My little case on wheels sat beside my chair,
My heart felt torn in two and I felt some despair,

Soaring through the sky I felt at peace with life,
Down below the toy town cars glinted in the strife,
Magic fairy lights all twinkled on the map of France,
As the airline staff started their aisle feeding dance.



I leave behind a piece of me each time I hug goodbye,
To my son, my two daughters, my grandchildren, how I cry,
One in London, one in Spain, one resides quite near,
But parting isn’t easy from the ones you hold so dear.

I waited on the ward for my treatment that is free,
With gratitude I wonder how they donated it for me,
We always take for granted all the things around us,
Until one day a wakeup calls us to a different bus.

Now each day is precious even though I am so tired,
I want to be an astronaut that never is retired,
I want to take my little case and visit every place,
It gives me hope to help me cope with a smile upon my face.

Watch and Wait

By David McIntosh

I’ve got Blood Cancer!
Don’t worry it’s just low risk
Only Watch and Wait


By Kate D

“You look well” you say,
brackets, (“for someone with cancer.)
And I think,
“Do I?
Do I really?
Because I don’t feel well at all.”

Peel off my steroid mask,
The wig and the rosy drug induced glow,
And you will see pain
And sing a different tune.

If I wore a scarf on my head,
turban - style, had a plaster cast or a
walking stick,
You would know .

I haven’t.
So you don’t.
But let me reassure you,
if you could feel the pain in my joints,
shooting as a bullet does
minute by minute,
or worse,
taking you unawares.

If you could feel
legs and arms like jelly
refusing to obey commands.

If you got stuck and
and had to phone
for help.

If you lost all your independence.
If you had all those things, then
you would know and never
say those words to anyone -

How are you?

By Kate D

Do you really want to know how I am?
Are you interested in
how I’m feeling today,
yesterday and tomorrow?
Then be prepared to listen.
Not with a sideways tilt of your head
and a look of sympathy with
nodding accompaniment.
Not with “I know” or
“I knew someone who…”
“My mum/aunt/sister/ brother/
cat and dog…"

If you ask the question
It deserves investment;
Investment in time
to find out that, actually,
I’m not ok,
that life is rubbish.
That for me,
my life has been lived.
Are you prepared to find out
about my suicidal thoughts,
my pain, my anger and grief?
Or are you being polite and feeling that
you have to ask, that it’s the right thing
to say?
And the answer you want is,
“I’m fine” or “Ok”.


By Kate D

Today I can
be in the sun
and absorb its warmth,
eyes shut ,
listening to everyday
sounds or
sit and read,
drink coffee;
being able to linger,
not gulp it down in haste
before the next thing
I must do.

I can bake scones,
watch the sunflowers
open their petals
to the early morning sun,
gently walk by the river and
listen to the breeze in the grasses,
the running of the water.

I can notice colours in flowers,
(in close up),
faded and bright
side by side, being
visited by bees and butterflies
who hover over the buddlia
dipping antennae into
the flowers one by one.

I can notice the patterns and shapes
of their wings,
see the shapes of the clouds and
watch as they shift
from white to grey.

I can take my time to
look at paintings in a house
nearby without rushing to be at
the next thing on my list.

I can do these things today.
Tomorrow, who knows?
But today I can.


Have you?

By Chris Davis

Have you someone who loves you,
Waiting when you die?
Or will you be alone,
No one t!ovate, or cry.

Will you spend forever, without love,
And all alone?
Or someone who love you,
Making forever a happy home?

Have you spread your love around,
To the people who surround?
Or used your way through life,
Leaving pain or needless strife?

Today, have you told someone"I love you"
And held them in your arms,
And made them feel safe, warm,
Protected from life's harms

Hell is where the loveless go,
To rot through to the core,
But that is not for me, nor thee,
For our souls will love, forever more.


Chemotherapy at home: less visits to the hospital and better quality of life

Research FOR Patients

-For an informed and empowered opinion-
Have you made your clinical paper accessible yet?

Written by Janet Hayden - Lead Myeloid Clinical Nurse Specialist - King’s College Hospital

MDS specialist nurse Janet Hayden gave two talks at our recent London Patient meeting at King’s College Hospital.

The first one was a report about the MDS International Symposium in Copenhagen, which she attended thanks to a travel grant from MDS UK. The symposium included a 1 day nurse programme, attended by nurses from several countries.

Janet says:

It is important that those of us lucky enough to attend these events get the opportunity to share that learning and knowledge back at base camp and especially to the MDS patient community who may not readily have access to some of this knowledge via other forums . So I have attempted to summarise some of these main points which may be of interest to you.

Janet says:

The program this year was heavily scientific. The presentations showed the ever increasing complexity of both evolution of MDS and the diagnosis. it is clear that the science has moved on tremendously in the past decade. The list of somatic mutations acquired in MDS is ever growing and the understanding of which of these genes does not respond or does respond continues to evolve. Challenges remain due to the heterogeneity (patients having more than one acquired mutation) that presents major challenges for treatment strategies.

A large team from Denmark presented their news and developments for patient services. These services included a Chemotherapy at Home, or mobile chemotherapy option, enabling patients to lead as normal a life as possible, whilst receiving their treatment. It also covered a patient peer to peer support scheme, as well as an exercise regime to help boost energy for AML and MDS patients.

Chemotherapy at Home scheme at King’s College Hospital

Her second talk introduced the Chemotherapy at Home scheme that will soon be in place at King’s College Hospital.

Click here or on the image to read and download Janet Hayden's presentation.

The Benefits for Patients

From the patient point of view there are a number of patients who struggle with travelling and travel costs. They experience long waiting times, increasing time off work for the patient and their carer.

In addition, the fact that they do not need to stay at the hospital environment while receiving treatment reduces their risk of infection so patients may choose chemotherapy at home to avoid the regular trips to the hospital.

The Benefits for the NHS

Moving care out of a hospital setting, is an important goal for the Institute’s and the broader NHS. There is evidence that it improves patient experience and quality of life, while reducing NHS burden and costs. As it releases capacity from busy outpatient clinics the scheme will help to improve NHS ability to deliver effective care.

The scheme has proven to be the preferred option by patients in Birmingham and other areas. Both King's College Hospital NHS and Guy's and St Thomas' NHS Foundation Trust staff are very supportive of the initiative, citing the positive impact it could have on patients.

Chemo at Home could be financially sustainable, and cheaper for the Institute than traditional clinics.

Chemotherapy at home in Spain

Would like to speak to KCH MDS nurses Janet Hayden or Geke Ong?

As ever, if you would like to speak to KCH MDS nurses Janet Hayden or Geke Ong, they are available during our MDS meetings at King’s.

These meetings are free and open to all patients in the UK.

The next London meeting is planned for 18th November. Click here for details of our next London Meeting.

Click here for dates and venues for all our patient meetings in the UK.

ACE-536-MDS-002 (Luspatercept)

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

ACE-536-MDS-002 (Luspatercept)

  1. SUB-TYPE OF MDS:Lower Risk MDS patients who require red cell transfusions but have not received Erythropoietin
  2. SEVERITY OF MDS: IPSS-R Very Low, Low or Intermediate Risk MDS
  3. NAME OF DRUG: Luspatercept
  4. Aims and benefits: To compare the safety and efficacy of Luspatercept versus epoetin alfa for treating anaemia in patients who require red cell transfusions.
    Luspatercept promotes red blood cell formation by regulating the growth of red blood cells during the late-stage of their development. It works differently to erythropoietin.
    This is a Phase 3 Randomized Study between Luspatercept and Epoetin alfa.

Read More

FG-4592-082 (Roxadustat) Clinical Trial Open to Recruitment

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

FG-4592-082 (Roxadustat)

  1. SUB-TYPE OF MDS:Lower Risk MDS With Low Red Blood Cell Transfusion Burden
  2. SEVERITY OF MDS: IPSS-R classification very low, low or intermediate risk with <5% blasts
  3. NAME OF DRUG: Roxadustat
  4. Aims and benefits: To determine whether Roxadustat is safe and effective in treating anaemia in patients with Primary Lower Risk Myelodysplastic Syndrome and Low Red Blood Cell Transfusion Burden.
    Roxadustat is an oral preparation that stimulates erythropoiesis (production of red cells) by increasing the body’s production of the hormone erythropoietin and it regulates the way in which the body uses iron. This study is a Phase 3 Randomized Double-Blind Placebo-Controlled Study in which there is a treatment period of 52 weeks and a 4 week end of treatment assessment.

Read More

Spotted in London this morning: a mysterious figure raising awareness of MDS & blood cancer

Mystery red figure in London Train

Mystery figure spotted next to a surprised Londoner on the train

Exclusive photos given anonymously to MDS UK have captured the moment a mysterious red creature seemed to walk on the streets of London raising awareness of MDS on Blood Cancer Awareness Month.

In one the photos, the red figure appears reading the newspaper on the train, while next to it a surprised Londoner makes desperate attempts to ignore it by looking at her phone.

Red figure and passersby at London during Blood Cancer Awareness Month

Passersby Amused!

Passersby on the train station appeared amused by the creature and were not afraid of sharing a ride on the escalators with the seemingly supernatural being.

In many images, the red figure can be seen displaying a sign attracting attention to MDS UK Patient Support Group!

Taxi drivers and tourists at London main attractions were today reminded by the outlandish creature that September is Blood Cancer Awareness Month, and many people next to them may suffer from this “invisible” disease.

Red figure in London during Blood Cancer Awareness Month

Have you seen the red mystery figure?

According to members of the charity, the supernatural being has done an amazing job at raising awareness of MDS.

The CEO of MDS UK, Sophie Wintrich, said: "We are looking for the mystery red figure to thank it immensely on behalf of MDS patients and their families."

Online users have however questioned whether the photos are real or not.

September: Blood Cancer Awareness Month

Make Blood Cancer Visible 2019

September is #BloodCancerAwarenessMonth.

MDS UK Patient Support Group, together with colleagues from Anthony Nolan, Bloodwise, CLL Support Association, CML Support, Leukaemia Care, Lymphoma Action, Myeloma UK, and Waldenstrom's Macroglobulinemia (WMUK), joined Make Blood Cancer Visible, an awareness campaign sponsored by Janssen UK.

This year, the theme is “Connecting the dots”, aimed at encouraging people to identify the many symptoms that can be experienced by people with blood cancer.

Additionally, throughout the month, MDS UK will posting poems on the theme of blood cancer written by our talented MDS UK member, KateD and other MDS patients,  starting with her M.D.S. poem we published in our June Newsletter.

Blood cancer is the third biggest cancer killer in the UK, claiming the lives of more than 15,000 people each year – more than breast cancer or prostate cancer. We believe that making blood cancer more visible will help people identify symptoms earlier, strengthen the community of people affected by blood cancer and help us to fund lifesaving research.

Help us raise awareness with the general public this September by sharing Kate's MDS Poems, or sending your own, and spreading the facts on this "Connecting the dots" infographic.

M.D.S. A Poem by Kate D.

My Day Starts.
I Must Do Something,
but then remember;
I can’t always do what I used to.
It Mostly Doesn’t Show
to those who don’t know.

Most Days Show how life used to be
before my Many Daily Struggles began
and Mild Depression Set in.
My Dog Sits on my shoulder.
But it Mostly Doesn’t Show
to those who don’t know.

Most Doctors Strive to do
what is best for the patient;
Many Don’t Spot the tell - tale signs,
are confused and perfunctory because
there are Multiple Different Symptoms
that confuse and delay.

My Marrow’s Diagnosis’ State is not
a good one; in fact,
My Diagnosis Stinks, but
it Mostly Doesn’t Show
to those who don’t know.

Medicinal Drugs Start.
I May Die Slowly or stay like this
for years yet as it
Mostly Doesn’t Show
to those who don’t know.

There are More Daily Struggles
for people like me
who have this fatigue,
these aching joints and bones,
this marrow that doesn’t work,
these days of despair.

Many Don’t Survive.
But I am not the worst and
for those in the know,
it Mostly Does Show
bravery, honesty, resilience.

Many Days Sort themselves out
in hospital waiting rooms on
hard plastic chairs,

Most Doctors Smile and ask how I am,
and continue to Make Some Diagnosis
if they know and can show
me that My Daily Struggle,
my MDS is Myelodysplastic Syndrome.

Make Blood Cancer Visible 2019 Infographic: Connecting the dots

Make Blood Cancer Visible 2019 Infographic: Connecting the dots

Watch Laurence Llewelyn-Bowen's story for #MakeBloodCancerVisible

Laurence Llewelyn-Bowen is the official ambassador for Make Blood Cancer Visible 2019.

We thank Janssen UK for sponsoring this work and making this awareness campaign possible. Without their help and organization, this type of work would not have been possible.

Familial/inherited MDS: rare but important to keep in mind

Research FOR Patients
-For an informed and empowered opinion-
Have you made your clinical paper accessible yet?

Is MDS likely to be passed down from parent to child?

Written by Prof Jude Fitzgibbon, Prof Tom Vulliamy and Prof Inderjeet Dokal, Queen Mary University of London

When a patient is first diagnosed with myelodysplastic syndrome (MDS), one of the most frequent questions posed is whether the disease is likely to be passed down from parent to child, and if other family members could conceivably develop this malignancy too.

Conventionally, heritable (i.e. passed from parent to child) forms of MDS are thought to be rare and are typically, NOT considered to run in families.

Our research group at Queen Mary University of London (QMUL), with funding from the charity Bloodwise, have been collecting and storing blood and bone marrow samples from these rare patients and their families in order to better understand the nature of the faulty genes responsible for inherited MDS. This research is important for the individual families, as it provides valuable
information for treatment of the disease, assessing risk and genetic counselling, but it also offers a unique opportunity to identify the critical early genetic events that give rise or predispose patients to MDS.

Jude Fitzgibbon talks with Sophie Wintrich about familial MDS. Watch the video

Since 2016, inherited forms of myeloid malignancies, including MDS, have been included as a separate disease entity in the World Health Organisation (WHO) classification of haematological cancers.

This is leading to a greater awareness on behalf of haematologists regarding the existence of these forms of disease, enabling more tailored management of this group of at-risk individuals.

This is important, as patients with ‘familial MDS’ (i.e. with a predisposing mutation present in every cell) tend to develop symptoms at a much younger age compared to people with ‘sporadic disease’ (i.e. mutations are restricted to the MDS only).

We also appreciate that MDS can arise as part of a wider syndrome, with many patients/families initially exhibiting bone marrow failure syndromes such as Fanconi anemia, dyskeratosis congenita, and Shwachman–Diamond syndrome which often subsequently lead to MDS.

Why is it important to identify patients with familial MDS?

Our research is demonstrating that there isn’t a singly mutated gene responsible for familial MDS but many different genes,
some of which are also mutated in sporadic forms of the disease (RUNX1, GATA2). In comparison other mutations (in the germline) appear enriched or exclusive to inherited forms of MDS (DDX41, SAMD9) and this is offering researchers novel insights into the causes of MDS and the prospect of developing better treatments for all MDS patients.

It is, therefore, important that, when a new patient is diagnosed with MDS in the clinic, steps are taken to determine whether the disease has a significant genetic-inherited component. This is crucial, as in some subtypes of inherited/familial MDS subsequent therapy must be modified.

  • For example, if a patient has MDS associated with an underlying telomerase mutation then the chemotherapy conditioning regimen performed prior to a bone marrow transplant has to be reduced.
  • Equally, a haematologist would want to ensure that, in selecting bone marrow/stem cell donors, an asymptomatic family member with the same genetic defect is not used as the donor as the recipient could go on to develop MDS again at a later time point./li>

Germline vs Somatic (Sporadic) Mutation

Which services does the research group provide?

In order to facilitate identification and genetic categorization of inherited/familial MDS our research group (in collaboration with the Genetics Laboratory at Birmingham and support from Bloodwise) provides genetic testing in such cases. This means if a clinician suspects that their patient may have a significant genetic component they can send blood samples directly to our laboratory.

Indeed, in the future, our expectation is that every MDS patient will have a molecular profile performed as part of their overall management, to identify the specific mutations that are exclusive to their MDS and to assess if there is a significant inherited component, linked to their disease, where a mutation is present in all cells in the patient’s body.

We are also able to provide specific advice on the management of patients if a genetic defect is found in one of the many genes that are associated with inherited/familial MDS by contacting us directly (email

Furthermore, if a genetic defect is not found in one of the known familial MDS genes and there is a strong clinical suspicion for familial MDS (for example, if there is a history of multiple MDS cases in the family) then these samples are put forward for research studies aimed at new gene discovery.

In summary:

  • Familial/inherited MDS is a very heterogeneous and complicated disorder. It is thought to be rare but the precise figures on its incidence and prevalence are not known.
  • Over the last 20 years many genes have been identified that are responsible for familial/inherited predisposition to MDS and they have highlighted the importance of making specific modifications to therapy to achieve optimal outcomes.
  • Our ongoing research programme at QMUL provides genetic testing for all of these genes as well as a strong focus on identifying new disease genes where current genetic tests fail to identify a defect in at-risk families.

MDS UK Patient Support Group Newsletter – June 2019

Our 10th edition of the MDS UK Newsletter is now out!

Read all about:

Patient's Stories - Living with MDS:

    • Bergit Kuhle: B12 meets MDS; Michael Bower; Bernard E Burke; Shareen Rouvray - Part 1; John and Sandra; Poetry by Kate

Research - Progress in the diagnosis and treatment of MDS:

    • European MDS Registry, Prof David Bowen; Familial/inherited MDS: rare but important to keep in mind, Professors Jude Fitzgibbon, Tom Vulliamy, Inderjeet Dokal Queen Mary University of London; A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia, Professor Simon Stanworth; Online Consultations with an MDS expert, Prof David Bowen; Data – a patient’s new best friend, Dr Thomas Coats

Fundraising Successes:

    • London Marathon 2019; Turks Head 10k fun run; and a lot more!

Here to help:

    • How support groups and technology can assist in communication, Dr Pavel Peter Kotoucek, FRCPath Haematology Department, Broomfield Hospital, Chelmsford; Making the most of your consultation; A a very successful Patient Information Forum in Harrogate; Regional groups update and more

Read More

Precision medicine is coming to the clinic to treat MDS

Research FOR Patients
-For an informed and empowered opinion-
Have you made your clinical paper accessible yet?

by Niels Jensen

What is precision medicine?

In precision medicine the basic idea is to develop a treatment for the specific cancer of individual patients based on a genetic understanding of their disease. Precision medicine has also been called personalized medicine or targetted medicine.

The basic idea is not completely new. Already in November 2013 Esquire Magazine reported the development of a treatment specifically for Stephanie Lee's colon cancer . The treatment effect had been verified on a banana fly, but the board of oncology at Mount Sinai in New York hesitated to give the experimental treatment to the patient and opted for a more conventional treatment. Read the story in Esquire

In Denmark, a collaboration between clinicians at Rigshospitalet and researchers at the Copenhagen University Biotech Research and Innovation Center (BRIC) has systematized a procedure for the development of a precision treatment for each MDS or leukemia patient who is signed up for trial, which has very few exclusion criteria, and straight forward inclusion criteria: you must have either MDS or leukemia and being treated at one of seven hematological centers in Denmark.

Read the full article: New Research Centre to improve personalized treatment for Danish patients with blood cancers

How does precision medicine work?

When a patient signs up for the trial, they are given a standard protocol treatment depending on the disease and the stage of the disease.

While the patient gets the protocol treatment' clinicians and researchers get to work: blood and bone marrow samples are collected from the patient. The patient's tumor cells are then screened in the labs against treatment effect from one or two of more than 400 already commercially available drugs.

If a drug or mixture of drugs shows a positive effect on the patient's cancer cells, then the second step is initiated. This involved growing the patient's cancer cells in the lab. Once enough cells are available they are injected into a mouse together with some of the microenvironment from the patient's bone marrow.

Then the researcher treats the mouse with the drug or drug mixture showed as having a positive effect during the laboratory screening.

If the mouse is successfully treated, then the clinicians have a precision medicine which, in Denmark, can be legally offered to the patient in the clinic.

Doctors in Denmark are allowed to use drugs off-label if they have evidence that the treatment works. This has been done for many years with EPO-like substances to improve red blood cell counts in low risk MDS patients.

Simultaneously, a whole genome next generation sequencing of the samples from the patient is performed to identify the specific mutations in the patient's cancer cells. This helps researchers to understand why a particular drug or drug mixture have a positive effect, and add the laboratory screening.

Precision Medicine - A specific drug for each genetic mutation

Professor Kirsten Grønbæk: "While we try to treat a specific patient, we also learn something for the benefit of future patients"

A scientific article published by the University of Copenhagen, Danish Research Center for Precision Medicine of Blood Cancer, explains that the program aims at improving the immediate and long-term outcome for blood cancer patients by coordinating and strengthening ongoing blood cancer research into a program pursuing research questions and integrating results from bench-to-bedside and bedside-to-bench.

The goal is to optimize the use of already approved drugs, identify new targets for therapy, develop novel therapies, test potential novel drugs in pre-clinical models, and collaborate with pharmaceutical companies on developing new drugs and test these and other novel drugs in Phase I-II clinical trials.

Professor Kirsten Grønbæk, PTH Professor and Chief Physician at Rigshospitalet, says:

Via 'drug screening' the cancer stem cells from the individual patient could be exposed to 400 different drugs.

In this way, we hope to find the medicine that accurately affects the individual's cancer stem cells, which is the cause for the cancer to return.

At the same time, we will try to find the molecular changes that indicate that this is the perfect treatment. For some patients, we will immediately find one or more drugs that work, but not for all who are in the need for treatment.

The idea is that while we try to treat a specific patient, we also learn something for the benefit of future patients.

The equipment for this trial have been financed by a grant from the Novo Nordic Foundation. A grant from the Danish Cancer Society covers the expenses for the first three years, and also access to the trial across the country. The trial was conceived by a collaboration between clinician Kirsten Grønbæk, and BRIC researchers Kristian Helin (currently part time at Memorial Sloan Kettering) and Bo Porse.

Clinical Trials open to recruitment in the UK

Team MDS at the Great North Run on September 8 2019

The Great North Run: a 13.1 mile journey from Newcastle's city centre to the coast in South Shields

The Great North Run, which took place on Sunday 8 September 2019, is the largest half marathon in the world, taking place annually in North East England each September.

An amazing team of 11 run for MDS UK Patient Support Group:

You can make a GREAT difference to MDS patients TODAY

Every donation, big or small, helps us maintain our

FREE services to MDS patients!


Free donations by shopping